Novo Nordisk A/S (LON:0QIU)
London flag London · Delayed Price · Currency is GBP · Price in DKK
448.49
+12.75 (2.92%)
At close: Jul 24, 2025

Novo Nordisk Company Description

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.

It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas.

The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy.

The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application.

The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space.

Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Novo Nordisk A/S
CountryDenmark
Founded1923
IndustryPharmaceutical Preparations
Employees77,349
CEOLars Jorgensen

Contact Details

Address:
Novo Alle 1
Bagsvaerd, 2880
Denmark
Phone45 44 44 88 88
Websitenovonordisk.com

Stock Details

Ticker Symbol0QIU
ExchangeLondon Stock Exchange
Share ClassClass B Shares
Fiscal YearJanuary - December
Reporting CurrencyDKK
ISIN NumberDK0062498333
SIC Code2834

Key Executives

NamePosition
Lars Fruergaard JorgensenPresident, Chief Executive Officer and Member of Management Board
Karsten Munk KnudsenExecutive Vice President, Chief Financial Officer and Member of the Management Board
Henrik Ehlers WulffExecutive Vice President, Head of Product Supply, Quality and IT and Member of the Management Board
Camilla SylvestExecutive Vice President, Head of Commercial Strategy and Corporate Affairs and Member of the Management Board
Dr. Martin Holst LangeExecutive Vice President, Head of Development and Member of the Management Board
Monique CarterExecutive Vice President, Head of People and Organisation and Member of Management Board
Dr. Marcus Schindler Ph.D.EVice President, Head of Research and Early Development, Chief Scientific Officer & Member of the Management Board
Maziar Mike DoustdarExecutive Vice President, Head of International Operations and Member of the Management Board
Douglas J. LangaExecutive Vice President, Head of North America Operations and Member of Management Board
Ludovic HelfgottExecutive Vice President, Head of Rare Disease and Member of Management Board